one
third
death
infecti
diseas
worldwid
viral
origin
although
hundr
virus
known
caus
human
diseas
mainstay
antivir
research
develop
remain
focus
direct
antivir
agent
daa
inhibit
specif
viral
protein
individu
virus
one
lock
one
key
approach
result
two
major
drawback
current
antivir
therapi
narrow
spectrum
therapeut
coverag
emerg
drug
resist
drawback
inflam
two
daunt
challeng
first
develop
new
drug
slow
expens
take
least
ten
year
averag
cost
us
billion
second
natur
viru
emerg
unpredict
one
lock
one
key
approach
imposs
provid
rapid
countermeasur
respond
global
crisi
viru
emerg
evidenc
recent
epidem
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
chikungunya
ebola
zika
virus
thu
new
antivir
approach
urgent
need
write
natur
materi
joshua
jackman
report
antivir
approach
term
lipid
envelop
antivir
disrupt
lead
develop
broadspectrum
antivir
therapi
author
demonstr
amphipath
peptid
ahd
deriv
first
amino
acid
hepat
c
viru
hcv
nonstructur
protein
fig
potent
antivir
activ
zika
dengu
yellow
fever
japanes
enceph
chikungunya
virus
concentr
requir
inhibit
viral
replic
nm
concentr
requir
caus
cytotox
remark
treatment
zika
virusinfect
mice
peptid
even
start
therapi
day
three
postinfect
protect
diseas
death
without
advers
effect
ntermin
region
hcv
known
associ
endoplasm
reticulum
membran
infect
cell
studi
interact
ntermin
protein
lipid
membran
cho
et
al
serendipit
discov
ah
peptid
could
potent
ruptur
importantli
ah
peptid
select
ruptur
liposom
diamet
nm
sizedepend
liposom
disrupt
determin
abil
ah
peptid
sens
differ
degre
membran
specif
liposom
nm
high
membran
curvatur
suscept
ah
peptidemedi
pore
format
fig
top
critic
densiti
pore
form
membran
lysi
occur
fig
bottom
contrast
liposom
nm
low
membran
curvatur
suscept
ah
peptidemedi
pore
format
thu
lysi
agreement
liposom
result
test
virus
prone
ah
peptid
inhibit
fall
within
disrupt
rang
liposom
size
flavivirus
nm
chikungunya
viru
nm
bunyavirus
nm
human
immunodefici
viru
nm
contrast
virus
larger
size
vaccinia
viru
well
cell
membran
less
sensit
peptid
result
suggest
ah
peptid
may
also
inhibit
untest
envelop
virus
long
virion
nm
besid
ah
peptid
chisari
colleagu
also
found
peptid
repres
amino
acid
hcv
broad
spectrum
antivir
potenc
peptid
differ
virus
much
weaker
current
ah
peptid
possibl
due
differ
peptid
length
amino
acid
sequenc
inde
mutagenesi
analysi
show
amphipath
structur
well
amino
acid
composit
critic
peptid
antivir
sinc
chiral
essenti
antivir
activ
current
ahd
peptid
synthes
damino
acid
rather
lamino
acid
suscept
proteolyt
dchiral
improv
peptid
pharmacokinet
stabil
halflif
time
h
mice
addit
ahd
peptid
cross
brainpenetr
properti
ideal
potenti
treatment
neurotroph
virus
inde
improv
potenc
pharmacokinet
brainpenetr
properti
ahd
peptid
translat
excel
efficaci
vivo
treatment
zika
virusinfect
mice
ahd
peptid
reduc
viral
load
blood
organ
well
reduct
inflammatori
cytokin
weight
loss
death
fig
specif
treatment
ahd
peptid
decreas
death
rate
peptid
abil
access
brain
significantli
enhanc
antivir
activ
central
nervou
system
protect
brain
function
infect
mice
indic
normal
level
target
host
factor
essenti
viru
life
cycl
valid
antivir
approach
approach
led
develop
maraviroc
clinic
approv
hiv
drug
inhibit
host
protein
coreceptor
hiv
compar
direct
antivir
agent
hosttarget
antivir
approach
offer
advantag
higher
barrier
resist
emerg
sinc
viral
mutat
less
abl
compens
loss
essenti
host
cofactor
addit
differ
virus
share
common
host
factorspathway
viral
replic
compound
target
share
host
factorspathway
could
broad
antivir
activ
develop
ahd
peptid
understand
structur
peptid
sens
disrupt
virion
help
design
futur
inhibitor
abil
optim
shorten
peptid
keep
potenc
reduc
drug
cost
importantli
achiev
observ
advers
effect
level
noael
preclin
safeti
test
advanc
ahd
peptid
clinic
trial
overal
current
studi
repres
breakthrough
advanc
lead
concept
new
class
broadspectrum
antivir
therapi
